Related Experiment Video
Updated: Mar 4, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Biologic Rescue With Tocilizumab: A Case of Refractory Chronic Pericardial Effusion in Systemic Sclerosis
Ramses Delgadillo1, Elliot Roufeh1, Bianca Lavelle2
1Department of Medicine, Olive View-UCLA Medical Center, Sylmar, California, USA.
Refractory pericardial effusions in systemic sclerosis (SSc) can be driven by interleukin-6 (IL-6). Tocilizumab, an IL-6 receptor antagonist, effectively treated a patient with SSc and a large pericardial effusion when standard therapies failed.
Area of Science:
- Rheumatology
- Immunology
- Cardiology
Background:
- Pericardial effusions in systemic sclerosis (SSc) are typically mild.
- Large or persistent effusions are uncommon but can significantly impact patient health.
More Related Videos
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
06:59Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Related Concept Videos
Pericarditis III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Pericarditis IV: Nursing Management
Myocarditis III: Medical Management
Pericarditis I: Introduction
Cardiomyopathy IV: Restrictive Cardiomyopathy